Patients who have been diagnosed with AML, CML, or MDS and are18 years old or older, may be able to participate in a clinical trial evaluating a new therapy.
PR1 peptide vaccine may be able stimulate your immune system to control your disease.
Therapy with the PR1 peptide vaccine entails a course of one to several subcutaneous injections, typically does not require hospitalization or supportive therapy, and is administered on an out-patient basis. According to results of the Phase 1/2 studies so far, the PR1 peptide vaccine has a good safety profile, causes little if any discomfort, and has been well tolerated by patients who have been treated to date.
If you are interested or know someone who may be interested in enrolling in our current clinical trials for the PR1 Peptide vaccine, please contact the relevant study directors in the links below:
PR1 Peptide Clinical trials for AML
This study is a registration (Phase III) study that will test the safety and efficacy of the PR1 Peptide vaccine for patients with AML in remission.
PR1 Peptide Clinical trials for CML:
This study will test the safety of the PR1 Peptide vaccine that may increase the number of immune cells responding to the CML disease cells, and thereby slow progression of the illness.
PR1 Peptide Clinical trials for MDS:
Giving vaccine therapy together with GM-CSF may kill more cancer cells.]This phase II trial is studying how well giving vaccine therapy together with GM-CSF works in treating patients with low-risk or intermediate-risk myelodysplastic syndrome.
PR1 peptide vaccine may be able stimulate your immune system to control your disease.
Therapy with the PR1 peptide vaccine entails a course of one to several subcutaneous injections, typically does not require hospitalization or supportive therapy, and is administered on an out-patient basis. According to results of the Phase 1/2 studies so far, the PR1 peptide vaccine has a good safety profile, causes little if any discomfort, and has been well tolerated by patients who have been treated to date.
If you are interested or know someone who may be interested in enrolling in our current clinical trials for the PR1 Peptide vaccine, please contact the relevant study directors in the links below:
PR1 Peptide Clinical trials for AML
This study is a registration (Phase III) study that will test the safety and efficacy of the PR1 Peptide vaccine for patients with AML in remission.
PR1 Peptide Clinical trials for CML:
This study will test the safety of the PR1 Peptide vaccine that may increase the number of immune cells responding to the CML disease cells, and thereby slow progression of the illness.
PR1 Peptide Clinical trials for MDS:
Giving vaccine therapy together with GM-CSF may kill more cancer cells.]This phase II trial is studying how well giving vaccine therapy together with GM-CSF works in treating patients with low-risk or intermediate-risk myelodysplastic syndrome.
